+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Uric Acid-lowering Drugs Market - Global Forecast 2026-2032- Product Image
Uric Acid-lowering Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Uric Acid-lowering Drugs Market - Global Forecast 2026-2032

  • Report

  • 198 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6147606
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Uric Acid-lowering Drugs Market is projected to reach USD 4.54 Billion in 2026. It is expected to continue growing at a CAGR of 8.79%, reaching USD 7.51 Billion by 2032.

Uric Acid-Lowering Drugs: Executive Overview

Uric acid-lowering drugs are used to reduce serum urate and prevent recurrent gout flares, urate crystal deposition, and related complications. The therapeutic landscape includes xanthine oxidase inhibitors, uricosuric medicines, and uricase-based treatments, with selection shaped by disease severity, kidney function, cardiovascular considerations, drug interactions, and treatment tolerance. Clinical practice increasingly emphasizes a treat-to-target approach, sustained adherence, and individualized monitoring rather than episodic management of acute symptoms alone.

Treatment Is Shifting Toward Earlier, Individualized Disease Control

The landscape is evolving from flare-focused care toward long-term disease modification. Guideline-led urate targets, dose titration, renal-adjusted prescribing, and prophylaxis during treatment initiation are becoming central to care pathways. Clinicians are also paying greater attention to comorbid hypertension, chronic kidney disease, obesity, diabetes, and cardiovascular disease, because these conditions influence both treatment choice and outcomes. Patient education, adherence support, laboratory monitoring, and clearer escalation pathways remain important determinants of effectiveness.

Artificial Intelligence Is Strengthening Diagnosis, Monitoring, and Adherence Support

Artificial intelligence can contribute across the care pathway by identifying patients at risk of recurrent flares, supporting interpretation of laboratory and imaging data, and helping clinicians recognize patterns associated with poor treatment response or adverse events. Digital tools may also personalize reminders, education, and follow-up based on medication-taking behavior and serum urate results. However, clinical validation, transparent algorithms, privacy safeguards, bias monitoring, and clinician oversight are essential before these applications influence prescribing decisions. AI is most useful as a decision-support layer that complements, rather than replaces, medical judgment.

Regional Insights: Guideline Adoption and Access Shape Treatment Patterns

In North America, emphasis is placed on treat-to-target management, specialty care, and integration with chronic-disease services, while affordability and adherence remain practical concerns. Europe continues to reflect structured guideline implementation, renal and cardiovascular risk assessment, and differences among national reimbursement systems. Asia-Pacific combines substantial disease burden with varied access, prescribing traditions, and diagnostic capacity across Australia, China, India, Japan, and South Korea. Latin America, including Brazil and Mexico, faces uneven access to specialist care and laboratory monitoring. The Middle East, particularly GCC health systems, is characterized by expanding clinical capacity alongside lifestyle-related risk factors. Africa remains highly diverse, with access, diagnosis, medicine availability, and continuity of care often constrained by health-system resources.

Group Insights: Economic and Institutional Blocs Show Diverse Priorities

ASEAN markets are shaped by differences in healthcare financing, urbanization, medicine access, and specialist availability, making adaptable treatment pathways important. BRICS members span highly varied regulatory, reimbursement, and public-health environments, with local manufacturing and essential-medicine access influencing implementation. The European Union benefits from shared scientific and regulatory frameworks but retains national differences in reimbursement and clinical delivery. G7 systems generally have stronger diagnostic infrastructure and pharmacovigilance capabilities, while still addressing adherence, health inequities, and aging populations. GCC countries are investing in integrated and digitally enabled care, whereas NATO members reflect broad variation in healthcare organization despite overlapping priorities around resilience, supply continuity, and chronic-disease management.

Country Insights: Local Guidelines, Comorbidities, and Access Remain Decisive

Australia combines established primary care with attention to renal disease and medication safety. Brazil and Mexico continue to require approaches that account for unequal specialist access and varying continuity of treatment. Canada and the United States emphasize guideline-based titration, comorbidity management, and patient adherence, while affordability and insurance design influence persistence. China and India present large and diverse care environments in which urban-rural differences, diagnostic access, and clinician education are important. France, Germany, Italy, Spain, and the United Kingdom operate within mature European systems, but reimbursement rules, prescribing norms, and referral pathways differ. Japan and South Korea place strong emphasis on monitoring, aging-related comorbidities, and structured clinical care. Russia faces variation in access and continuity across regions, reinforcing the value of reliable supply and standardized treatment protocols.

Industry Priorities: Improve Treat-to-Target Execution and Patient Persistence

Industry leaders should support evidence-based education on urate targets, titration, prophylaxis, and adherence without encouraging inappropriate self-medication. Partnerships with healthcare providers can strengthen laboratory monitoring, renal-risk assessment, pharmacovigilance, and shared decision-making. Access strategies should account for public reimbursement, generic availability, supply reliability, and local care capacity. Digital adherence services and AI-enabled tools should be introduced only with clinical validation, privacy protection, and measurable outcomes. Evidence generation should focus on diverse populations, real-world persistence, safety in multimorbidity, and practical implementation across primary, specialty, and community settings.

Research Methodology: Evidence-Led Synthesis of the Therapeutic Landscape

This executive summary is structured around established clinical principles for urate-lowering therapy and a comparative review framework covering treatment modalities, care pathways, comorbidities, access conditions, and health-system variation. Regional, group, and country narratives synthesize differences in clinical infrastructure, reimbursement, regulatory context, epidemiology, and implementation capacity. Artificial-intelligence applications are assessed according to potential clinical utility, validation requirements, governance, and patient-safety considerations. The analysis intentionally excludes market estimates, market sizing, market shares, forecasts, and company-specific assessments.

Conclusion: Durable Outcomes Depend on Integrated, Personalized Care

Uric acid-lowering therapy is increasingly positioned as long-term disease control rather than short-term flare response. The strongest care models combine guideline-concordant urate targeting, individualized medicine selection, proactive safety monitoring, comorbidity management, and sustained patient engagement. Regional and country differences mean that implementation must be adapted to local access and health-system realities. Artificial intelligence can improve identification, monitoring, and adherence support when deployed responsibly, but clinical oversight and robust evidence remain indispensable.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Uric Acid-lowering Drugs Market, by Drug Class
7.1. Introduction
7.2. Recombinant Uricases
7.2.1. Pegloticase
7.2.2. Rasburicase
7.3. Uricosuric Agents
7.3.1. Benzbromarone
7.3.2. Lesinurad
7.3.3. Probenecid
7.4. Xanthine Oxidase Inhibitors
7.4.1. Allopurinol
7.4.2. Febuxostat
7.4.3. Topiroxostat
8. Uric Acid-lowering Drugs Market, by Branded Versus Generic
8.1. Introduction
8.2. Branded
8.3. Generic
9. Uric Acid-lowering Drugs Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous Injection
10. Uric Acid-lowering Drugs Market, by Dosage Form
10.1. Introduction
10.2. Capsule
10.3. Powder For Injection
10.4. Solution For Injection
10.5. Tablet
11. Uric Acid-lowering Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Uric Acid-lowering Drugs Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care
12.4. Hospitals
13. Uric Acid-lowering Drugs Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Uric Acid-lowering Drugs Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Uric Acid-lowering Drugs Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Apotex Inc.
17.2. Dr. Reddy's Laboratories Ltd.
17.3. Horizon Therapeutics plc
17.4. Lupin Limited
17.5. Novartis AG
17.6. Sandoz International GmbH
17.7. Sun Pharmaceutical Industries Ltd.
17.8. Takeda Pharmaceutical Company Limited
17.9. Teijin Pharma Co., Ltd.
17.10. Teva Pharmaceutical Industries Ltd.
17.11. Viatris Inc.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Uric Acid-lowering Drugs Market, Years Considered for the Study
FIGURE 2. Global Uric Acid-lowering Drugs Market, Research Design
FIGURE 3. Global Uric Acid-lowering Drugs Market, Research Framework
FIGURE 4. Global Uric Acid-lowering Drugs Market, Data Triangulation
FIGURE 5. Global Uric Acid-lowering Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Uric Acid-lowering Drugs Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 7. Global Uric Acid-lowering Drugs Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2025 vs 2032 (%)
FIGURE 9. Global Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Uric Acid-lowering Drugs Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 13. Global Uric Acid-lowering Drugs Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Uric Acid-lowering Drugs Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global Uric Acid-lowering Drugs Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Uric Acid-lowering Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Uric Acid-lowering Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Uric Acid-lowering Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Uric Acid-lowering Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Uric Acid-lowering Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Uric Acid-lowering Drugs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Uric Acid-lowering Drugs Market Segmentation & Coverage
TABLE 2. Global Uric Acid-lowering Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 4. Global Recombinant Uricases Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Recombinant Uricases Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Recombinant Uricases Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Pegloticase Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Pegloticase Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Pegloticase Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Rasburicase Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Rasburicase Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Rasburicase Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Uricosuric Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Uricosuric Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Uricosuric Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Benzbromarone Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Benzbromarone Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Benzbromarone Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Lesinurad Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Lesinurad Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Lesinurad Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Probenecid Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Probenecid Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Probenecid Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Xanthine Oxidase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Xanthine Oxidase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Xanthine Oxidase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Allopurinol Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Allopurinol Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Allopurinol Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Febuxostat Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Febuxostat Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Febuxostat Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Topiroxostat Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Topiroxostat Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Topiroxostat Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 38. Global Branded Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Branded Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Branded Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Generic Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Generic Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Generic Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 45. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Subcutaneous Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Subcutaneous Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Subcutaneous Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 55. Global Capsule Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Capsule Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Capsule Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Powder For Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Powder For Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Powder For Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Solution For Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Solution For Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Solution For Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 68. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 78. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global Uric Acid-lowering Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Asia-Pacific Uric Acid-lowering Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Asia-Pacific Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 90. Asia-Pacific Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 91. Asia-Pacific Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 92. Asia-Pacific Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 93. Asia-Pacific Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 94. Asia-Pacific Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 95. Asia-Pacific Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 96. Asia-Pacific Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 97. Asia-Pacific Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 98. North America Uric Acid-lowering Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. North America Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 100. North America Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 101. North America Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 102. North America Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 103. North America Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 104. North America Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 105. North America Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 106. North America Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 107. North America Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 108. Latin America Uric Acid-lowering Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. Latin America Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 110. Latin America Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 111. Latin America Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 112. Latin America Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 113. Latin America Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 114. Latin America Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 115. Latin America Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 116. Latin America Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 117. Latin America Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 118. Europe Uric Acid-lowering Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 119. Europe Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 120. Europe Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 121. Europe Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 122. Europe Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 123. Europe Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 124. Europe Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 125. Europe Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 126. Europe Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 127. Europe Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 128. Middle East Uric Acid-lowering Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. Middle East Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 130. Middle East Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 131. Middle East Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 132. Middle East Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 133. Middle East Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 134. Middle East Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 135. Middle East Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 136. Middle East Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 137. Middle East Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 138. Africa Uric Acid-lowering Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 139. Africa Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 140. Africa Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 141. Africa Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 142. Africa Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 143. Africa Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 144. Africa Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 145. Africa Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 146. Africa Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 147. Africa Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 148. Global Uric Acid-lowering Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 149. ASEAN Uric Acid-lowering Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 150. ASEAN Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 151. ASEAN Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 152. ASEAN Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 153. ASEAN Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 154. ASEAN Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 155. ASEAN Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 156. ASEAN Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 157. ASEAN Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 158. ASEAN Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 159. GCC Uric Acid-lowering Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 160. GCC Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 161. GCC Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 162. GCC Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 163. GCC Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 164. GCC Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 165. GCC Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 166. GCC Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 167. GCC Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 168. GCC Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 169. European Union Uric Acid-lowering Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 170. European Union Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 171. European Union Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 172. European Union Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 173. European Union Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 174. European Union Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 175. European Union Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 176. European Union Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 177. European Union Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 178. European Union Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 179. BRICS Uric Acid-lowering Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 180. BRICS Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 181. BRICS Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 182. BRICS Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 183. BRICS Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 184. BRICS Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 185. BRICS Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 186. BRICS Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 187. BRICS Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 188. BRICS Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 189. G7 Uric Acid-lowering Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 190. G7 Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 191. G7 Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 192. G7 Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 193. G7 Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 194. G7 Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 195. G7 Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 196. G7 Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 197. G7 Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 198. G7 Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 199. NATO Uric Acid-lowering Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 200. NATO Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 201. NATO Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 202. NATO Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 203. NATO Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 204. NATO Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 205. NATO Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 206. NATO Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 207. NATO Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 208. NATO Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 209. Global Uric Acid-lowering Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 210. United States Uric Acid-lowering Drugs Market Size, 2017-2032 (USD Million)
TABLE 211. United States Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 212. United States Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 213. United States Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 214. United States Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 215. United States Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 216. United States Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 217. United States Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 218. United States Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 219. United States Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 220. Canada Uric Acid-lowering Drugs Market Size, 2017-2032 (USD Million)
TABLE 221. Canada Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 222. Canada Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 223. Canada Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 224. Canada Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 225. Canada Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 226. Canada Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 227. Canada Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 228. Canada Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 229. Canada Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 230. Mexico Uric Acid-lowering Drugs Market Size, 2017-2032 (USD Million)
TABLE 231. Mexico Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 232. Mexico Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 233. Mexico Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 234. Mexico Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 235. Mexico Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 236. Mexico Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 237. Mexico Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 238. Mexico Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 239. Mexico Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 240. Brazil Uric Acid-lowering Drugs Market Size, 2017-2032 (USD Million)
TABLE 241. Brazil Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 242. Brazil Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 243. Brazil Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 244. Brazil Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 245. Brazil Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 246. Brazil Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 247. Brazil Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 248. Brazil Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 249. Brazil Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 250. United Kingdom Uric Acid-lowering Drugs Market Size, 2017-2032 (USD Million)
TABLE 251. United Kingdom Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 252. United Kingdom Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 253. United Kingdom Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 254. United Kingdom Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 255. United Kingdom Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 256. United Kingdom Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 257. United Kingdom Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 258. United Kingdom Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 259. United Kingdom Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 260. Germany Uric Acid-lowering Drugs Market Size, 2017-2032 (USD Million)
TABLE 261. Germany Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 262. Germany Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 263. Germany Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 264. Germany Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 265. Germany Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 266. Germany Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 267. Germany Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 268. Germany Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 269. Germany Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 270. France Uric Acid-lowering Drugs Market Size, 2017-2032 (USD Million)
TABLE 271. France Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 272. France Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 273. France Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 274. France Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 275. France Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 276. France Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 277. France Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 278. France Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 279. France Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 280. Russia Uric Acid-lowering Drugs Market Size, 2017-2032 (USD Million)
TABLE 281. Russia Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 282. Russia Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 283. Russia Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 284. Russia Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 285. Russia Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 286. Russia Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 287. Russia Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 288. Russia Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 289. Russia Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 290. Italy Uric Acid-lowering Drugs Market Size, 2017-2032 (USD Million)
TABLE 291. Italy Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 292. Italy Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 293. Italy Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 294. Italy Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 295. Italy Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 296. Italy Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 297. Italy Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 298. Italy Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 299. Italy Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 300. Spain Uric Acid-lowering Drugs Market Size, 2017-2032 (USD Million)
TABLE 301. Spain Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 302. Spain Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 303. Spain Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 304. Spain Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 305. Spain Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 306. Spain Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 307. Spain Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 308. Spain Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 309. Spain Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 310. China Uric Acid-lowering Drugs Market Size, 2017-2032 (USD Million)
TABLE 311. China Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 312. China Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 313. China Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 314. China Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 315. China Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 316. China Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 317. China Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 318. China Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 319. China Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 320. India Uric Acid-lowering Drugs Market Size, 2017-2032 (USD Million)
TABLE 321. India Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 322. India Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 323. India Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 324. India Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 325. India Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 326. India Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 327. India Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 328. India Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 329. India Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 330. Japan Uric Acid-lowering Drugs Market Size, 2017-2032 (USD Million)
TABLE 331. Japan Uric Acid-lowering Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 332. Japan Uric Acid-lowering Drugs Market Size, by Recombinant Uricases, 2017-2032 (USD Million)
TABLE 333. Japan Uric Acid-lowering Drugs Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 334. Japan Uric Acid-lowering Drugs Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 335. Japan Uric Acid-lowering Drugs Market Size, by Branded Versus Generic, 2017-2032 (USD Million)
TABLE 336. Japan Uric Acid-lowering Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 337. Japan Uric Acid-lowering Drugs Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 338. Japan Uric Acid-lowering Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 339. Japan Uric Acid-lowering Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 340. Australia Uric Acid-lowering Drugs Market Size, 2017-2032 (USD Millio

Companies Mentioned

  • Apotex Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Horizon Therapeutics plc
  • Lupin Limited
  • Novartis AG
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teijin Pharma Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Related Topics

Related Reports

Oral Antiepileptic Drug Market - Global Forecast 2026-2032 - Product Image

Oral Antiepileptic Drug Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Antibody Oligonucleotide Conjugates Drug Market - Global Forecast 2026-2032 - Product Image

Antibody Oligonucleotide Conjugates Drug Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Pediatric Drugs Market Report 2026 - Product Image

Pediatric Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Mouth Ulcers Treatment - Global Strategic Business Report - Product Image

Mouth Ulcers Treatment - Global Strategic Business Report

  • Report
  • 394 Pages
  • Global
From
Global Pediatric Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Global Pediatric Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 119 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.